We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stellar Announces Exclusive Option to License Clostridium Difficile Technology
News

Stellar Announces Exclusive Option to License Clostridium Difficile Technology

Stellar Announces Exclusive Option to License Clostridium Difficile Technology
News

Stellar Announces Exclusive Option to License Clostridium Difficile Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stellar Announces Exclusive Option to License Clostridium Difficile Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stellar Biotechnologies, Inc. has announced that it has entered into an agreement with the University of Guelph (Ontario, Canada) for the exclusive option to license technology for the development of a vaccine candidate against Clostridium difficile infection (“CDI”).

Clostridium difficile is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. CDI causes severe diarrhea and life-threatening intestinal conditions such as colitis.

CDI is a major and growing cause of mortality and morbidity in hospitalized patients. In the United States, incidence of CDI is at a record high with 336,600 cases reported in 2009 and projected to continue to increase.

“The use of non-antibiotic-based approaches to control Clostridium difficile colonization may offer an important treatment option for CDI,” said Herbert Chow, Ph.D., Stellar Vice President of Product Development.

Chow continued, “Stellar is committed to identifying promising vaccine candidates such as for CDI or other disease targets that may be synergistic with our KLH platform.”

Professor Mario A. Monteiro (University of Guelph) commented that, "It is very gratifying to our research group that Stellar is taking the lead in commercializing our C. difficile vaccine technology, and to see that our scientific discoveries may soon be available to the public and provide a significant positive impact on global health".

The cost of CDI-related treatments in the U.S. and European countries is estimated at more than $7 billion a year.

The recent emergence and spread of hyper-virulent strains of Clostridium difficile further underscore the importance of developing novel approaches to preventing and treating CDI.

Advertisement